Supplementary Tables 1 - 17, Figures 1 - 3 from <i>PIK3CA</i> and <i>PTEN</i> Gene and Exon Mutation-Specific Clinicopathologic and Molecular Associations in Colorectal Cancer
Authors: Day Fiona L. , Jorissen Robert N. , Lipton Lara , Mouradov Dmitri , Sakthianandeswaren Anuratha , Christie Michael , Li Shan , Tsui Cary , Tie Jeannie , Desai Jayesh , Xu Zheng-Zhou , Molloy Peter , Whitehall Vicki , Leggett Barbara A. , Jones Ian T. , McLaughlin Stephen , Ward Robyn L. , Hawkins Nicholas J. , Ruszkiewicz Andrew R. , Moore James , Busam Dana , Zhao Qi , Strausberg Robert L. , Gibbs Peter , Sieber Oliver M. 
Published: April 2023

<p>PDF file - 716K, Supplementary Table 1. Somatic PIK3CA exon 9 and 20 mutations detected in 1,093 patients with sporadic CRC. Supplementary Table 2. Somatic PTEN exon 3 to 8 mutations detected in 744 patients with sporadic CRC. Supplementary Table 3. Pathogenicity predictions for PTEN missense mutations. Supplementary Table 4. Clinicopathological and molecular characteristics of sporadic CRC according to PIK3CA mutation status for microsatellite stable (n = 924) and microsatellite instability-high (n=159) cases. Supplementary Table 5. Relationship of clinicopathological and molecular characteristics of sporadic CRC with PIK3CA exon 9 or 20 mutation status, for (A) microsatellite stable (n = 923) and (B) microsatellite instability-high (n=159) cases. Supplementary Table 6. Multivariate logistic regression analysis for overall PIK3CA gene mutation relative to wild-type. Model 1 includes age at diagnosis, gender, tumor location, stage, differentiation, mucinous histology, MSI, CIMP, KRAS, BRAF and PTEN mutation status. Supplementary Table 7. Multivariate logistic regression analysis for PIK3CA exon 9 mutation relative to wild-type. Model 1 includes age at diagnosis, gender, tumor location, stage, differentiation, mucinous histology, MSI, CIMP, KRAS, BRAF and PTEN mutation status. Supplementary Table 8. Multivariate logistic regression analysis for PIK3CA exon 20 mutation relative to wild-type. Model 1 includes age at diagnosis, gender, tumor location, stage, differentiation, mucinous histology, MSI, CIMP, KRAS, BRAF and PTEN mutation status. Supplementary Table 9. Multivariate logistic regression analysis for PIK3CA exon 20 mutation relative to exon 9 mutation. Model 1 includes age at diagnosis, gender, tumor location, stage, differentiation, mucinous histology, MSI, CIMP, KRAS, BRAF and PTEN mutation status. Supplementary Table 10. Clinicopathological and molecular characteristics of sporadic CRC according to PTEN mutation status for microsatellite stable (n = 645) and microsatellite instability-high (n=98) cases. Supplementary Table 11. Multivariate logistic regression analysis for PTEN gene mutation relative to wild-type. Model 1 includes age at diagnosis, gender, tumor location, stage, differentiation, mucinous histology, MSI, CIMP, KRAS, BRAF and PTEN mutation status. Supplementary Table 12. Univariate and multivariate Cox proportionalhazards analysis of disease-free survival for patients with resected stage II or III CRC according to PIK3CA mutation status, with mutations classified into exon 9 or exon 20 mutations. * P<0.05 Supplementary Table 13. Univariate and multivariate Cox proportionalhazards analysis of disease-free survival for patients with resected stage II or III CRC according to PIK3CA status for patients who (A) did not receive 5-FUbased adjuvant therapy (n = 244) or (B) did receive 5-FU-based adjuvant therapy (n = 345). * P<0.05. Supplementary Table 14. Univariate and multivariate Cox proportional-hazards analysis of disease-free survival for patients with resected stage II or III CRC according to PIK3CA mutation status, with mutations classified into exon 9 or exon 20 mutations, for patients who (A) did not receive 5-FU-based adjuvant therapy (n = 244) or (B) did receive 5-FU-based adjuvant therapy (n = 345). * P<0.05. Supplementary Table 15. Univariate and multivariate Cox proportional-hazards analysis of disease-free survival for patients with resected stage II or III CRC according to PTEN status for patients who (A) did not receive 5-FU-based adjuvant therapy (n = 170) or (B) did receive 5-FU-based adjuvant therapy (n = 211). * P<0.05. Supplementary Table 16. Univariate and multivariate Cox proportionalhazards analysis of disease-free survival for patients with resected stage II or III CRC according to mutation of PI3K pathway components PIK3CA or PTEN. * P<0.05 Supplementary Table 17. Studies included in the integrated multi-cohort analysis for associations between clinicopathological and molecular characteristics of CRC with PIK3CA exon 9 and 20 mutation status. Supplementary Figure 1. Distribution of 55 somatic PTEN exon 3 to 8 mutations detected in 43 sporadic CRCs. Supplementary Figure 2. Integrated multi-cohort analysis for associations between clinicopathological and molecular characteristics of CRC with PIK3CA exon 9 or 20 mutation status. Supplementary Figure 3. Integrated multi-cohort analysis for associations between clinicopathological and molecular characteristics of CRC with PIK3CA exon 9 or 20 mutation status excluding data from this study.</p>